^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
LightMix® BRAF V600E/K Kit

Company:
Roche
Type:
CE Marked
Related tests:
Evidence Level:
Resistant: B - Late Trials

[BRAF V600E-Colorectal Cancer-cetuximab]

Title:
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Excerpt:
BRAF V600E mutation indicated poor prognosis in patients with KRAS wild-type disease in both treatment groups, with those whose tumors carried BRAF mutations having a worse outcome for all efficacy end points compared with those whose tumors were wild-type (Table 3; Fig 2C).
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2010.33.5091
Trial ID: